• Explore /
  • Poster
  • / A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.

A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.

Abstract Poster

Authors

null

Samantha Mary Jaglowski

The Ohio State University, Columbus, OH

Samantha Mary Jaglowski , Jeffrey Alan Jones , Joseph M. Flynn , Leslie A. Andritsos , Kami J. Maddocks , Jennifer Ann Woyach , Kristie A. Blum , Michael R. Grever , Susan Michelle Geyer , Nyla A. Heerema , Gerard Lozanski , Mona Stefanos , Nathan Hall , Veena Nagar , Brian Munneke , Jamie-Sue West , Jutta Neuenburg , Danelle Frances James , Amy J. Johnson , John C. Byrd

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Leukemia, Myelodysplasia, and Transplantation

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Leukemia

Clinical Trial Registration Number

NCT01217749

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 7009)

DOI

10.1200/jco.2014.32.15_suppl.7009

Abstract #

7009

Poster Bd #

1

Abstract Disclosures

Similar Posters

First Author: Paola Ghione

First Author: Paul M. Barr

First Author: Jacqueline Claudia Barrientos

First Author: Hun Ju Lee